Meningococcal disease
Meningococcal disease is an uncommon but dangerous bacterial infection that can cause meningitis, bloodstream infection, sepsis, long-term disability, or death within hours.
What meningococcal disease is
Meningococcal disease is any infection caused by Neisseria meningitidis. The bacteria can live in the nose and throat without causing illness, but if they invade the bloodstream or the lining around the brain and spinal cord, disease can become severe very quickly. Even with treatment, meningococcal disease can be fatal or leave lasting harm.
How it spreads
People spread meningococcal bacteria through respiratory and throat secretions, such as saliva or spit. Spread usually requires close or lengthy contact, such as living in the same household, kissing, or sharing space in some dormitory or military settings. Humans are the only reservoir for the bacteria.
Meningitis and bloodstream infection
Meningococcal meningitis occurs when bacteria infect the membranes around the brain and spinal cord. Bloodstream infection, also called meningococcemia, occurs when bacteria enter the blood and damage blood vessel walls. Both can appear suddenly, overlap with other illnesses at first, and progress to shock, organ damage, or death.
Symptoms
Meningitis symptoms often include fever, headache, stiff neck, nausea, vomiting, confusion, and sensitivity to light. Bloodstream infection can cause fever, chills, severe aches, rapid breathing, cold hands and feet, fatigue, diarrhea or vomiting, and a dark purple rash in later stages. Infants may be irritable, feed poorly, vomit, or have a bulging soft spot.
Risk factors
Anyone can get meningococcal disease, but risk is higher for infants, adolescents and young adults, people with certain immune conditions, people without a functioning spleen, microbiologists exposed to the bacteria, travelers to some outbreak or high-incidence regions, and people taking complement inhibitor medicines. Crowded living settings can also raise risk.
Diagnosis and treatment
Diagnosis can involve blood or cerebrospinal fluid testing, culture, molecular tests, and serogroup identification. Treatment should start quickly when meningococcal disease is suspected, usually with powerful antibiotics such as ceftriaxone or cefotaxime while test results are pending. Supportive hospital care may be needed for shock, breathing problems, seizures, or organ injury.
Protecting close contacts
Close contacts of a person with meningococcal disease may need antibiotic prophylaxis even if they feel well. Public-health teams identify who qualifies, choose the right medicine, and decide whether vaccination or outbreak control steps are needed. This close-contact work is urgent because secondary cases can occur soon after exposure.
Vaccines and serogroups
Meningococcal vaccines target specific serogroups. In the United States, MenACWY vaccination is recommended for all preteens and teens, while MenB vaccination is recommended for some high-risk people and may be used for adolescents and young adults based on shared clinical decision-making. Recommendations vary by country, risk group, age, and outbreak setting.
Why it matters
Meningococcal disease is rare enough to be missed but serious enough that delay can be catastrophic. It tests clinical recognition, emergency care, vaccine systems, laboratory capacity, and public-health response. A single case can trigger urgent work to protect contacts and prevent further spread.
What public health teams watch
Surveillance tracks cases, serogroups, outbreaks, age groups, vaccination history, antibiotic resistance, and disease trends. These data guide vaccine recommendations, outbreak vaccination campaigns, prophylaxis choices, and alerts to clinicians when cases rise or unusual strains appear.